Partnerships, Licensing, Investments and M&A Deals and Trends for March 2017 in Pharmaceuticals

Publisher Name :
Date: 01-May-2017
No. of pages: 78
Inquire Before Buying

GlobalData's "Partnerships, Licensing, Investments and M&A Deals and Trends for March 2017 in Pharmaceuticals" report is an essential source of data and trend analysis on partnerships, licensing, mergers and acquisitions (M&As) and financings in the pharmaceuticals industry. The report provides detailed information on partnership and licensing transactions, M&As, equity/debt offerings, private equity, and venture financing registered in the pharmaceuticals industry in March 2017. The report portrays detailed comparative data on the number of deals and their value in the last six months, subdivided by deal types, various therapy areas, and geographies. Additionally, the report provides information on the top financial advisory firms in the pharmaceuticals industry.

Data presented in this report is derived from GlobalData's proprietary in-house Pharmaceuticals eTrack deals database and primary and secondary research.

Scope


  • Analysis of the market trends for the pharmaceutical industry in the global arena.

  • Review of deal trends in the cardiovascular, central nervous system, dermatology, ear nose throat disorders, gastrointestinal, genito urinary system and sex hormones, hematological disorders, hormonal disorders, immunology, infectious disease, male health, metabolic disorders, mouth and dental disorders, musculoskeletal, oncology, ophthalmology, respiratory, toxicology, and women's health segments.

  • Analysis of partnerships, licensing, M&As, equity/debt offerings, private equity, and venture financing deals in the pharmaceutical industry.

  • Analysis of therapy areas which are very active in terms of venture capital financing, partnerships, licensing agreements, equity/debt offerings, and M&As.

  • Analysis of deals based on different payment modes, including upfront and milestone payments, primarily in partnerships and licensing agreements in the pharmaceutical industry.

  • Analysis of partnership and licensing deals based on clinical stage of development of products.

  • Summary of the pharmaceutical deals globally in the six months.

  • Information on the top deals happened in the pharmaceutical industry.

  • Geographies covered include - North America, Europe, Asia Pacific, South & Central America, and the Middle East & Africa.

  • League tables of financial advisors in M&As and equity/debt offerings. This includes key advisors such as Morgan Stanley, Credit Suisse, and Goldman Sachs.


Reasons to buy


  • Enhance your decision making capability in a more rapid and time sensitive manner.

  • Find out the major deal performing segments for investments in your industry.

  • Evaluate the types of companies which are entering into partnership or licensing agreements; divesting and acquiring assets.

  • Identify companies that are aggressively looking to raise capital in the market

  • Evaluate niche therapy areas that are receiving majority of the upfront and milestone payments in the pharmaceutical industry.

  • Identify the key venture capitalists, who are financing the pharmaceutical and biotech companies.

  • Evaluate the clinical development stages where majority of the partnerships and licensing agreements are happening.

  • Do deals with an understanding of how competitors are financed, and the mergers and partnerships that have shaped the pharmaceutical industry.

  • Identify growth segments and opportunities in each region within the industry.

  • Look for key financial advisors where you are planning to raise capital from the market or for acquisitions within the industry.

Partnerships, Licensing, Investments and M&A Deals and Trends for March 2017 in Pharmaceuticals

Table of Contents

1 Table of Contents 2
1.1 List of Tables 5
1.2 List of Figures 7

2 Pharmaceuticals & Healthcare, Global, Deal Summary 10
2.1 Pharmaceuticals & Healthcare, Global, Deal Analysis, March 2017 10
2.2 Pharmaceuticals & Healthcare, Global, Major Deals, March 2017 11
2.2.1 Valeant Pharma Raises USD2.4 Billion in Public Offering of Notes 11
2.2.2 Creat Group to Acquire Biotest in Tender Offer 12
2.2.3 Sanofi Enters into Co-Development Agreement with MedImmune 12
2.2.4 Thermo Fisher Scientific Prices Public Offering of 1.45% Notes Due 2027 for USD530 Million 12
2.2.5 Boston Scientific to Acquire Symetis for USD435 Million 13
2.3 Pharmaceuticals & Healthcare, Global, by Type, Number of Deals, March 2017 14
2.4 Pharmaceuticals & Healthcare, Global, by Type, Deal Values, March 2017 15

3 Pharmaceuticals and Healthcare, Global, Deals, Summary, by Type 16
3.1 Pharmaceuticals & Healthcare, Global, M&A, March 2017 16
3.1.1 Top M&A Deals in March 2017 17
3.1.2 Pharmaceuticals & Healthcare, Global, M&A Deals by Therapy Area, October 2016- March 2017 18
3.2 Pharmaceuticals & Healthcare, Global, Equity Offering Deals, March 2017 19
3.2.1 Top Equity Offering Deals in March 2017 20
3.2.2 Pharmaceuticals & Healthcare, Global, Equity Offering Deals by Therapy Area, October 2016- March 2017 21
3.3 Pharmaceuticals & Healthcare, Global, Private Equity and Venture Capital Deals, March 2017 22
3.3.1 Top PE/VC Deals in March 2017 23
3.3.2 Pharmaceuticals & Healthcare, Global, PE/VC by Therapy Area, March 2017 24
3.3.3 Pharmaceuticals & Healthcare, Global, Venture Capital Deals by Stage of Financing, March 2017 25
3.3.4 Pharmaceuticals & Healthcare, Global, Top Venture Financing Firms, August 2016-March 2017 26
3.3.5 Pharmaceuticals & Healthcare, Global, Top VC Backed Companies, August 2016-March 2017 27
3.4 Pharmaceuticals & Healthcare, Global, Partnership Deals, March 2017 28
3.5 Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, October 2016- March 2017 29
3.6 Pharmaceuticals & Healthcare, Global, Partnership Deals by Upfront and Milestone Payments and Deal Values (US$ m), March 2017 30
3.6.1 Pharmaceuticals & Healthcare, Global, Top Partnership Deals by Payment Mode, March 2017 31
3.7 Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, by Upfront and Milestone Payments and Deal Values (US$ m), October 2016- March 2017 32
3.8 Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, Number Of Deals, October 2016- March 2017 33
3.9 Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, Deal Values (US$ m), October 2016- March 2017 34
3.10 Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, by Upfront & Milestone Payments and Deal Values (US$ m), October 2016- March 2017 35

4 Pharmaceuticals & Healthcare, Global, Licensing Agreements, March 2017 36
4.1 Pharmaceuticals & Healthcare, Global, Licensing Agreements, March 2017 36
4.2 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, Upfront and Milestone Payments and Deal Values (US$ m), March 2017 37
4.3 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Total Deal Values (US$ m), October 2016- March 2017 38
4.4 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Upfront Payments and Milestone Payments (US$ m), October 2016- March 2017 39
4.5 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, Total Deal Values (US$ m), October 2016- March 2017 40
4.6 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, Upfront Payments and Milestone Payments (US$ m), October 2016- March 2017 42
4.6.1 Pharmaceuticals & Healthcare, Global, Top Licensing Agreements by Deal Value, March 2017 43
4.6.2 Pharmaceuticals & Healthcare, Global, Top Licensing Agreements, by Total Upfront Payments, March 2017 43
4.6.3 Pharmaceuticals & Healthcare, Global, Top Licensing Agreements by Total Milestone Payment, March 2017 44

5 Pharmaceuticals & Healthcare, Global, Deal Summary by Therapy Area 45
5.1 Pharmaceuticals & Healthcare, Global, Oncology Deals, March 2017 45
5.1.1 Oncology - Deals of the Month 46
5.2 Pharmaceuticals & Healthcare, Global, Central Nervous System Deals, March 2017 48
5.2.1 Central Nervous System - Deals of the Month 49
5.3 Pharmaceuticals & Healthcare, Global, Infectious Disease Deals, March 2017 50
5.3.1 Infectious Diseases - Deals of the Month 51
5.4 Pharmaceuticals & Healthcare, Global, Cardiovascular Deals, March 2017 53
5.4.1 Cardiovascular - Deal of the Month 54
5.5 Pharmaceuticals & Healthcare, Global, Immunology Deals, March 2017 55
5.5.1 Immunology - Deals of the Month 56
5.6 Pharmaceuticals & Healthcare, Global, Respiratory Deals, March 2017 58
5.6.1 Respiratory - Deal of the Month 59
5.7 Pharmaceuticals & Healthcare, Global, Metabolic Disorders, Deals, March 2017 61
5.7.1 Metabolic Disorders - Deal of the Month 62

6 Deal Summary by Geography 64
6.1 Pharmaceuticals & Healthcare, North America Deals, March 2017 64
6.1.1 North America - Deals of the Month 65
6.2 Pharmaceuticals & Healthcare, Europe, Deals, March 2017 67
6.2.1 Europe - Deals of the Month 68
6.3 Pharmaceuticals & Healthcare, Asia-Pacific, Regional Deals, March 2017 70
6.3.1 Asia-Pacific - Deals of the Month 71
6.4 Pharmaceuticals & Healthcare, Rest of the World, Deals, March 2017 72
6.4.1 Rest of the World - Deals of the Month 73

7 Pharmaceuticals & Healthcare, Global, Top Financial Advisors 74
7.1 Pharmaceuticals & Healthcare, Global, Top Financial Advisors, M&A, October 2016- March 2017 74
7.2 Pharmaceuticals & Healthcare, Global, Top Financial Advisors, Equity Offerings, October 2016- March 2017 75

8 Further Information 76
8.1 Methodology 76
8.2 About GlobalData 77
8.3 Contact Us 77
8.4 Disclosure information 78
8.5 Disclaimer 78

List of Tables

Table 1: Pharmaceuticals & Healthcare, Global, Deals Summary, Number of Deals and Deal Values (US$ m), October 2016- March 2017 11
Table 2: Pharmaceuticals & Healthcare, Global, Major Deals, March 2017 11
Table 3: Pharmaceuticals & Healthcare, Global, Number Of Deals and Deal Values (%), March 2017 15
Table 4: Pharmaceuticals & Healthcare, Global, M&A, Deals Summary, Number of Deals and Deal Values (US$ m), October 2016- March 2017 17
Table 5: Pharmaceuticals & Healthcare, Global, Top M&A Deals, March 2017 17
Table 6: Pharmaceuticals & Healthcare, Global, M&A, Deals Summary, Number of Deals and Deal Values (US$ m), by Therapy Area, October 2016- March 2017 18
Table 7: Pharmaceuticals & Healthcare, Global, Equity Offerings, Deals Summary, Number of Deals and Deal Values (US$ m), October 2016- March 2017 20
Table 8: Pharmaceuticals & Healthcare, Global, Top Equity Offering Deals, March 2017 20
Table 9: Pharmaceuticals & Healthcare, Global, Equity Offering Deals, Deals Summary, Number of Deals and Deal Values (US$ m), October 2016- March 2017 21
Table 10: Pharmaceuticals & Healthcare, Global, PE/VC, Deals Summary, Number of Deals and Deal Values (US$ m), October 2016- March 2017 23
Table 11: Pharmaceuticals & Healthcare, Global, Top PE/VC Deals, March 2017 23
Table 12: Pharmaceuticals & Healthcare, Global, PE/VC Deals by Therapy Area, Deals Summary, October 2016- March 2017 24
Table 13: Pharmaceuticals & Healthcare, Global, Venture Capital Deals by Stage of Financing, Number Of Deals and Deal Values (%), March 2017 26
Table 14: Pharmaceuticals & Healthcare, Global, Top Venture Financing Firms, Number of Deals and Deal Values (US$ m), October 2016- March 2017 27
Table 15: Pharmaceuticals & Healthcare, Global, Top VC Backed Companies, October 2016- March 2017 27
Table 16: Pharmaceuticals & Healthcare, Global, Partnerships, Number of Deals and Deal Values (US$ m), October 2016- March 2017 28
Table 17: Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, Number of Deals and Deal Values (US$ m), October 2016- March 2017 29
Table 18: Pharmaceuticals & Healthcare, Partnership Deals, Upfront and Milestone Payments and Deal Values (US$ m), October 2016- March 2017 30
Table 19: Pharmaceuticals & Healthcare, Global, Partnerships, Upfront and Milestone Payments and Deal Values (US$ m), March 2017 31
Table 20: Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, Upfront and Milestone Payments and Deal Values (US$ m), October 2016- March 2017 32
Table 21: Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, October 2016- March 2017 34
Table 22: Pharmaceuticals & Healthcare, Global, Partnership Deals by Upfront and Milestone Payment and Deal values (US$ m), October 2016- March 2017 35
Table 23: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, Deals Summary, Number of Deals and Deal Values (US$ m), October 2016- March 2017 36
Table 24: Pharmaceuticals & Healthcare, Global, Licensing Agreements, Deals Summary, Upfront and Milestone Payments and Deal Values (US$ m), October 2016- March 2017 37
Table 25: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Number of Deals and Deal Values (US$ m), October 2016- March 2017 38
Table 26: Pharmaceuticals & Healthcare, Global, Licensing Agreements by Therapy Area, by Upfront and Milestone Payments (US$ m), March 2017 39
Table 27: Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, October 2016- March 2017 41
Table 28: Pharmaceuticals & Healthcare, Global, Licensing Agreements by Therapy Area, by Upfront and Milestone Payments and Deal Values (US$ m), March 2017 42
Table 29: Pharmaceuticals & Healthcare, Global, Top Licensing Agreement Deals by Value, March 2017 43
Table 30: Pharmaceuticals & Healthcare, Global, Top Licensing Agreement Deals by Total Upfront Payments, March 2017 43
Table 31: Pharmaceuticals & Healthcare, Global, Top Licensing Agreement Deals by Total Milestone Payment, March 2017 44
Table 32: Pharmaceuticals & Healthcare, Global, Oncology, Deals Summary, Number of Deals and Deal Values (US$ m), October 2016- March 2017 46
Table 33: Pharmaceuticals & Healthcare, Global, Central Nervous System, Deals Summary, Number of Deals and Deal Values (US$ m), October 2016- March 2017 49
Table 34: Pharmaceuticals & Healthcare, Global, Infectious Diseases, Deals Summary, Number of Deals and Deal Values (US$ m), October 2016- March 2017 51
Table 35: Pharmaceuticals & Healthcare, Global, Cardiovascular, Deals Summary, Number of Deals and Deal Values (US$ m), October 2016- March 2017 54
Table 36: Pharmaceuticals & Healthcare, Global, Immunology, Deals Summary, Number of Deals and Deal Values (US$ m), October 2016- March 2017 56
Table 37: Pharmaceuticals & Healthcare, Global, Respiratory, Deals Summary, Number of Deals and Deal Values (US$ m), October 2016- March 2017 59
Table 38: Pharmaceuticals & Healthcare, Global, Metabolic Disorders, Deals Summary, Number of Deals and Deal Values (US$ m), October 2016- March 2017 62
Table 39: Pharmaceuticals & Healthcare, North America, Deals Summary, Number of Deals and Deal Values (US$ m), October 2016- March 2017 64
Table 40: Pharmaceuticals & Healthcare, Europe, Deals Summary, Number of Deals and Deal Values (US$ m), October 2016- March 2017 68
Table 41: Pharmaceuticals & Healthcare, Asia-Pacific, Deals Summary, Number of Deals and Deal Values (US$ m), October 2016- March 2017 71
Table 42: Pharmaceuticals & Healthcare, Rest of the World, Deals Summary, Number of Deals and Deal Values (US$ m), October 2016- March 2017 73
Table 43: Pharmaceuticals & Healthcare, Top Financial Advisors, M&A, Number of Deals and Deal Values (US$ m), October 2016- March 2017 74
Table 44: Pharmaceuticals & Healthcare, Global Top Financial Advisors, Equity Offerings, Number of Deals and Deal Values (US$ m), October 2016- March 2017 75

List of Figures

Figure 1: Pharmaceuticals & Healthcare, Global, Number of Deals and Deal Values (US$ m), October 2016- March 2017 10
Figure 2: Pharmaceuticals & Healthcare, Global, Number Of Deals (%), March 2017 14
Figure 3: Pharmaceuticals & Healthcare, Global, Deal Values (%), March 2017 15
Figure 4: Pharmaceuticals & Healthcare, Global, M&As, Number of Deals and Deal Values (US$ m), October 2016- March 2017 16
Figure 5: Pharmaceuticals & Healthcare, Global, M&As by Therapy Area, Number of Deals and Deal Values (US$ m), by Therapy Area, October 2016- March 2017 18
Figure 6: Pharmaceuticals & Healthcare, Global, Equity Offering Deals, Number of Deals and Deal Values (US$ m), October 2016- March 2017 19
Figure 7: Pharmaceuticals & Healthcare, Global, Equity Offering Deals by Therapy Area, Number of Deals and Deal Values (US$ m), October 2016- March 2017 21
Figure 8: Pharmaceuticals & Healthcare, Global, Private Equity and Venture Capital, Number of Deals and Deal Values (US$ m), October 2016- March 2017 22
Figure 9: Pharmaceuticals & Healthcare, Global, PE/VC Deals by Therapy Area, Number of Deals and Deal Values (US$ m), by Therapy Area, October 2016- March 2017 24
Figure 10: Pharmaceuticals & Healthcare, Global, Venture Capital Deals by Stage of Financing, Number Of Deals (%), March 2017 25
Figure 11: Pharmaceuticals & Healthcare, Global, Venture Capital Deals by Stage of Financing, Deal Values (%), March 2017 25
Figure 12: Pharmaceuticals & Healthcare, Global, Top Venture Financing Firms, Number of Deals and Deal Values (US$ m), October 2016- March 2017 26
Figure 13: Pharmaceuticals & Healthcare, Global, Partnerships, Number of Deals and Deal Values (US$ m), October 2016- March 2017 28
Figure 14: Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, Number of Deals and Deal Values (US$ m), October 2016- March 2017 29
Figure 15: Pharmaceuticals & Healthcare, Global, Partnership Deals, Upfront and Milestone Payments and Deal Values (US$ m), October 2016- March 2017 30
Figure 16: Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, Upfront and Milestone Payments and Deal Values (US$ m), October 2016- March 2017 32
Figure 17: Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, October 2016- March 2017 33
Figure 18: Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, October 2016- March 2017 34
Figure 19: Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, by Upfront & Milestone Payments and Deal Values (US$ m), October 2016- March 2017 35
Figure 20: Pharmaceuticals & Healthcare, Global, Licensing Agreements, Number of Deals and Deal Values (US$ m), October 2016- March 2017 36
Figure 21: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, Upfront and Milestone Payments and Deal Values (US$ m), October 2016- March 2017 37
Figure 22: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Number of Deals and Deal Values (US$ m), October 2016- March 2017 38
Figure 23: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Upfront and Milestone Payments and Deal Values (US$ m), October 2016- March 2017 39
Figure 24: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, Number Of Deals, October 2016- March 2017 40
Figure 25: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, Deal Values (US$ m), October 2016- March 2017 40
Figure 26: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, by Upfront and Milestone Payments and Deal Values (US$ m), March 2017 42
Figure 27: Pharmaceuticals & Healthcare, Global, Oncology, Number of Deals and Deal Values (US$ m), October 2016- March 2017 45
Figure 28: Pharmaceuticals & Healthcare, Global, Central Nervous System, Number of Deals and Deal Values (US$ m), October 2016- March 2017 48
Figure 29: Pharmaceuticals & Healthcare, Global, Infectious Diseases, Number of Deals and Deal Values (US$ m), October 2016- March 2017 50
Figure 30: Pharmaceuticals & Healthcare, Global, Cardiovascular, Number of Deals and Deal Values (US$ m), October 2016- March 2017 53
Figure 31: Pharmaceuticals & Healthcare, Global, Immunology, Number of Deals and Deal Values (US$ m), October 2016- March 2017 55
Figure 32: Pharmaceuticals & Healthcare, Global, Respiratory, Deals Summary, Number of Deals and Deal Values (US$ m), October 2016- March 2017 58
Figure 33: Pharmaceuticals & Healthcare, Global, Metabolic Disorders, Deals Summary, Number of Deals and Deal Values (US$ m), October 2016- March 2017 61
Figure 34: Pharmaceuticals & Healthcare, North America, Number of Deals and Deal Values (US$ m), October 2016- March 2017 64
Figure 35: Pharmaceuticals & Healthcare, Europe, Number of Deals and Deal Values (US$ m), October 2016- March 2017 67
Figure 36: Pharmaceuticals & Healthcare, Asia-Pacific, Number of Deals and Deal Values (US$ m), October 2016- March 2017 70
Figure 37: Pharmaceuticals & Healthcare, Rest of the World, Number of Deals and Deal Values (US$ m), October 2016- March 2017 72
Figure 38: Pharmaceuticals & Healthcare, Global, Top Financial Advisors, M&A, Number of Deals and Deal Values (US$ m), October 2016- March 2017 74
Figure 39: Pharmaceuticals & Healthcare, Global, Top Financial Advisors, Equity Offerings, Number of Deals and Deal Values (US$ m), October 2016- March 2017 75

  • Pharmaceutical Mergers and Acquisitions Market Insights 2019, Global and Chinese Analysis and Forecast to 2024
    Published: 19-Apr-2019        Price: US 3000 Onwards        Pages: 138
    Pharmaceutical Mergers and Acquisitions Market Insights 2019, Global and Chinese Scenario is a professional and in-depth study on the current state of the global Pharmaceutical Mergers and Acquisitions industry with a focus on the Chinese market. The report provides key statistics on the market status of the Pharmaceutical Mergers and Acquisitions manufacturers and is a valuable source of guidance and direction for companies and individuals interested in the industry. Overall, the report provide......
  • Pharmerging Contract Manufacturings Market Insights 2019, Global and Chinese Analysis and Forecast to 2024
    Published: 17-Feb-2019        Price: US 3000 Onwards        Pages: 135
    Pharmerging Contract Manufacturings Market Insights 2019, Global and Chinese Scenario is a professional and in-depth study on the current state of the global Pharmerging Contract Manufacturings industry with a focus on the Chinese market. The report provides key statistics on the market status of the Pharmerging Contract Manufacturings manufacturers and is a valuable source of guidance and direction for companies and individuals interested in the industry. Overall, the report provides an in-dept......
  • Global Co-promotion and Co-marketing Partnering Terms and Agreements in Pharma, Biotech & Diagnostics 2010-2018
    Published: 01-Oct-2018        Price: US 2995 Onwards        Pages: 344
    The Global Co-promotion and Co-marketing Partnering Terms & Agreements in Pharma, Biotech & Diagnostics 2010-2018 report provides comprehensive understanding and unprecedented access to the co-promotion and co-marketing partnering agreements entered into by the worlds leading healthcare companies. The Global Co-promotion and Co-marketing Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2010-2018 report provides comprehensive understanding and unprecedented access to the ......
  • Global Joint Venture Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2010-2018
    Published: 01-Oct-2018        Price: US 1995 Onwards        Pages: 348
    The Global Joint Venture Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2010-2018 report provides comprehensive understanding and unprecedented access to the joint venture partnering agreements entered into by the worlds leading healthcare companies. The Global Joint Venture Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2010-2018 report provides comprehensive understanding and unprecedented access to the joint venture deals and agreements entered i......
  • Global Royalty Financing Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2010-2018
    Published: 01-Oct-2018        Price: US 1995 Onwards        Pages: 350
    The Global Royalty Financing Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2010-2018 report provides comprehensive understanding and unprecedented access to the royalty financing partnering agreements entered into by the worlds leading healthcare companies. The Global Royalty Financing Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2010-2018 report provides comprehensive understanding and unprecedented access to the royalty financing agreem......
  • Global Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2012 to 2018
    Published: 01-Oct-2018        Price: US 2995 Onwards        Pages: 457
    The Global Co-development Partnering Terms and Agreements in Pharma, Biotech & Diagnostics 2012-2018 report provides comprehensive understanding and unprecedented access to the co-development deals and agreements entered into by the worlds leading healthcare companies. The Global Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2012-2018 report provides comprehensive understanding and unprecedented access to the co-development deals and agreements entered ......
  • Global Collaborative R&D Partnering Terms and Agreements in Pharma, Biotech & Diagnostics 2012-2018
    Published: 01-Oct-2018        Price: US 2995 Onwards        Pages: 2000
    The Global Collaborative R&D Partnering Terms & Agreements in Pharma, Biotech & Diagnostics 2012-2018 report provides comprehensive understanding and unprecedented access to the collaborative R&D partnering deals and agreements entered into by the worlds leading healthcare companies. The Global Collaborative R&D Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2012-2018 report provides comprehensive understanding and unprecedented access to the collaborative R&D deals an......
  • Global Academic and Non-Profit Partnering Terms and Agreements 2012-2018: Deal trends, players and financials
    Published: 01-Oct-2018        Price: US 2995 Onwards        Pages: 1000
    Global Academic and Non-Profit Partnering Terms and Agreements 2012 to 2018 report provides a detailed understanding and analysis of how and why companies enter Academic and Non-Profit partnering deals Global Academic and Non-Profit Partnering Terms and Agreements 2012 to 2018 report provides a detailed understanding and analysis of how and why companies enter Academic and Non-Profit partnering deals. These deals tend to be multicomponent, starting with collaborative R&D, and proceed to c......
  • Global Merger and Acquisition Terms and Agreements in Pharma, Biotech and Diagnostics 2012-2018
    Published: 01-Sep-2018        Price: US 2995 Onwards        Pages: 1000
    "Delivery of this report will take 1-3 days after purchase." The Global Merger and Acquisition Terms and Agreements in Pharma, Biotech and Diagnostics 2012-2018 report provides details of the latest merger and acquisition (M&A) agreements announced in the pharmaceutical, biotechnology, diagnostic and other lifescience sectors. Fully revised and updated, the report provides details of M&A agreements from 2012 to 2018. The report provides a detailed understan......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - sales@rnrmarketresearch.com / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs